Please login to the form below

Not currently logged in
Email:
Password:

Gilead wins over IQWiG with new Eviplera data

German HTA body says it can now recognise the triple HIV pill has 'added benefit

German HTA body IQWiG

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) has reversed its negative recommendation for Gilead's Eviplera after the pharma company provided key study data.

The triple combination HIV pill was ruled in April to provide no additional benefit by the health technology assessment (HTA) advisers, despite rilpivirine – one of the Eviplera's components – being backed.

IQWiG said Gilead had failed to provide “important data” for Eviplera's first assessment under Germany's AMNOG legislation.

As a result IQWiG was unable to say whether it provided “added benefit”, in effect meaning it would hand a negative recommendation to the drug pricing watchdog the German Federal Joint Committee (G-BA), which is responsible for issuing final guidance.

IQWiG's new ruling was made possible after Gilead provided additional data from ongoing studies in the form of new subgroup analyses for Eviplera during the commenting period for the guidance.

“There is now proof that also in the fixed combination with emtricitabine and tenofovir disoproxil, rilpivirine offers a considerable added benefit for men infected with HIV-1. For women, the available studies provide corresponding indications. This matches the result of the dossier assessment of April 2012 on rilpivirine as a single agent,” IQWiG said in a statement.

Data from the manufacturer also suggested Eviplera may have fewer neurological side effects than monotherapy rilpivirine, but “a few uncertainties” in Gilead's analysis meant this was just an “indication of lesser harm”, IQWiG said. 

Eviplera combines Tibotec and Johnson & Johnson's Edurant (rilpivirine) with Gilead's own double therapy Truvada (emtricitabine and tenofovir disproxil). 

It was approved in Europe in November last year as a once-daily treatment for patients starting antiretroviral therapy for the first time.

16th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's premier medical animation company. Over the past 20 years we have created over 350 mechanism-of-action (MoA)...

Latest intelligence

Anthill_icon_Green_17_Multi-channel.png
Can you access your own content?
The rapid development of multichannel communication opens new opportunities to provide high-value experiences for healthcare professionals and gives you more places than ever to tell your product story. But unless...
How will capitated budgets affect NHS spending?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP...
Dissecting adherence to personalise patient support
Across the healthcare and pharmaceutical industries, the initiatives to better understand the patient journey and lower healthcare costs have been growing in magnitude. One solution that has repeatedly been raised...

Infographics